Indaptus Therapeutics raised $5.7 million through the sale of convertible promissory notes and warrants for R&D purposes. Indaptus Therapeutics, Inc., a clinical stage biotech company, announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results